HOPO Therapeutics
HOPO Therapeutics
Home
About
Company
People
Careers
FAQ
Our Focus Areas
Radiological Hazards
Lead Poisoning
Metals in Medicine
Our Science
Discovery & Development
HOPO-101
Publications
News
Contact
plutonium
238 Pu elimination profiles after delayed treatment with 3,4,3LI(1,2HOPO) in female and male Swiss-Webster mice
Dose-dependent efficacy and safety toxicology of hydroxypyridinonate actinide decorporation agents in rodents: towards a safe and effective human dosing regimen.
Two hydroxypyridinone-containing actinide decorporation agents, 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO), are being developed for the treatment of internal actinide contamination by chelation therapy. Dose-response efficacy profiles in mice were …
Cite
×